These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 19546801)

  • 1. Venous thromboembolism in lymphoma: how effectively are we treating patients?
    Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Daw HA
    Am J Clin Oncol; 2009 Oct; 32(5):521-3. PubMed ID: 19546801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of a pharmacist-managed anticoagulation service for breast cancer patients.
    Jones KL; Barnett C; Gauthier M; Boster B; Espirito JL; Michaud LB
    J Oncol Pharm Pract; 2012 Mar; 18(1):122-7. PubMed ID: 21364079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
    Thachil J
    Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures.
    Clark NP; Witt DM; Davies LE; Saito EM; McCool KH; Douketis JD; Metz KR; Delate T
    JAMA Intern Med; 2015 Jul; 175(7):1163-8. PubMed ID: 26010033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
    Schulman S; Kakkar AK; Goldhaber SZ; Schellong S; Eriksson H; Mismetti P; Christiansen AV; Friedman J; Le Maulf F; Peter N; Kearon C;
    Circulation; 2014 Feb; 129(7):764-72. PubMed ID: 24344086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center.
    Labrador J; González-Rivero J; Monroy R; Lozano FS; López-Corral L; Caballero MD; Bastida JM; González-Porras JR
    Thromb Res; 2016 Jun; 142():52-6. PubMed ID: 26922092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis.
    Ihaddadene R; Le Gal G; Delluc A; Carrier M
    Thromb Res; 2014 Jul; 134(1):93-5. PubMed ID: 24835673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.
    Willey VJ; Bullano MF; Hauch O; Reynolds M; Wygant G; Hoffman L; Mayzell G; Spyropoulos AC
    Clin Ther; 2004 Jul; 26(7):1149-59. PubMed ID: 15336480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The study of Chinese optimal anticoagulant range of warfarin for venous thromboembolism].
    Yang P; Wu QH; Luo XY; Kou L; Chen Z; Zhang YY; Zhou H
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(25):1762-5. PubMed ID: 19862981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periprocedural anticoagulation management of patients with venous thromboembolism.
    McBane RD; Wysokinski WE; Daniels PR; Litin SC; Slusser J; Hodge DO; Dowling NF; Heit JA
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):442-8. PubMed ID: 20139361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of venous thromboembolism in cancer patients.
    Petralia GA; Kakkar AK
    Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
    Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
    J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
    Douketis JD; Johnson JA; Turpie AG
    Arch Intern Med; 2004 Jun; 164(12):1319-26. PubMed ID: 15226166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.
    Soto-Cárdenas MJ; Pelayo-García G; Rodríguez-Camacho A; Segura-Fernández E; Mogollo-Galván A; Giron-Gonzalez JA
    Palliat Med; 2008 Dec; 22(8):965-8. PubMed ID: 18952751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.